Index of reports
> Cases with Dysphonia (4)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Covera-HS (Verapamil) where reactions include dysphonia. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Covera-HS side effects in 47 year old female
Reported by a consumer/non-health professional from United States on 2012-05-31
Patient: 47 year old female, weighing 73.0 kg (160.6 pounds)
Reactions: Migraine, Angina Pectoris, Joint Swelling, Dysphonia
Drug(s) suspected as cause:
Covera-HS
Dosage: form: tab
Administration route: Oral
Indication: Vasospasm
Start date: 2011-09-01
End date: 2011-12-01
Buspar
Administration route: Oral
Covera-HS
Dosage: form: tab
Administration route: Oral
Indication: Migraine
Start date: 2011-09-01
End date: 2011-12-01
Other drugs received by patient: Maxalt
Possible Covera-HS side effects in female
Reported by a physician from United States on 2012-05-03
Patient: female, weighing 68.0 kg (149.6 pounds)
Reactions: Migraine, Joint Swelling, Dysphonia, Angina Pectoris
Drug(s) suspected as cause:
Covera-HS
Dosage: 180 mg, 1x/day
Administration route: Oral
Indication: Vasospasm
Start date: 2011-09-01
End date: 2011-12-01
Covera-HS
Indication: Migraine
Buspar
Dosage: unk
Administration route: Oral
Other drugs received by patient: Maxalt
Possible Covera-HS side effects in female
Reported by a consumer/non-health professional from United States on 2011-10-07
Patient: female, weighing 73.0 kg (160.6 pounds)
Reactions: Migraine, Dysphonia, Joint Swelling
Drug(s) suspected as cause:
Buspar
Dosage: unk
Administration route: Oral
Covera-HS
Dosage: 180 mg, unk
Administration route: Oral
Indication: Vasospasm
Start date: 2011-08-31
Possible Covera-HS side effects in female
Reported by a physician from United States on 2011-10-03
Patient: female, weighing 73.0 kg (160.6 pounds)
Reactions: Migraine, Joint Swelling, Dysphonia
Drug(s) suspected as cause:
Buspar
Dosage: unk
Administration route: Oral
Covera-HS
Dosage: 180 mg, unk
Administration route: Oral
Indication: Vasospasm
Start date: 2011-08-31
|